Clinical studies for newly diagnosed IDH1- or IDH2-mutated AML with IDH inhibitors used as monotherapy, in combination with intensive chemotherapy or with 5-azacitidine for unfit patients are running [21]. This evidence concerns the gene IDH1 and acute myeloid leukemia.